眾生藥業(002317.SZ):鹽酸丙美卡因原料藥獲得化學原料藥上市申請批准通知書
格隆匯9月26日丨眾生藥業(002317.SZ)公佈,公司全資子公司廣東先強藥業有限公司於近日收到國家藥品監督管理局核准簽發的原料藥鹽酸丙美卡因《化學原料藥上市申請批准通知書》。
鹽酸丙美卡因是一種酯類表面麻醉劑,通過降低神經元對鈉的瞬間滲透性,穩定神經細胞膜,阻止神經衝動的產生和傳導,從而產生局麻效果。鹽酸丙美卡因滴眼液適應症為眼科表面麻醉,應用於:眼壓計測量眼內壓;手術縫合及取異物;結膜及角膜刮片,前房角鏡檢查,三面鏡檢查及其他需表面麻醉的操作。
根據米內網數據庫顯示,鹽酸丙美卡因滴眼液2021至2023年在中國城市公立醫院及中國城市實體藥店的銷售額合計分別為人民幣4,556萬元,5,321萬元,7,472萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.